top of page



Get recognized for your obesity medicine expertise by sitting for the next Pan American Board of Obesity Medicine (PABOM) Certification Exam 2023. 

PABOM Certification Exam will be held in Brazil in 2023 and will take place on:


  • May 28, 2023, Sunday / 08:00 am / 08:00 pm

  • May 29, 2023, Monday / 08:00 am / 05:00 pm


English, Spanish and Portuguese version = SOLD OUT

  • July 29, 2023, Saturday / 08:00 am / 08:00 pm

  • July 30, 2023, Sunday / 08:00 am / 05:00 pm



English, Spanish and Portuguese version = SOLD OUT.


  •  May 29, 2023, Monday / 05:00 pm / 08:00 pm


English, Spanish and Portuguese version = SOLD OUT

  • July 30, 2023, Sunday / 05:00 pm / 08:00 pm



English, Spanish and Portuguese version = SOLD OUT

Costão do Santinho Logo.png






1. Be an active Member. The annual fee for PABOM Active Membership is $ 48 (U.S. currency).

2. Proof of an active, unrestricted medical license. 

3. Proof of active board certification, residency or fellowship in one of the following medical specialties:  

Andrology / Anesthesiology / Angiology / Aviation medicine / Cardiology / Cardiovascular/ Thoracic Surgery / Clinical Immunology / Allergy / Critical Care Medicine / Dermatology / Diagnostic Radiology / Emergency Medicine / Endocrinology and Metabolism / Family Medicine / Gastroenterology / General Internal Medicine / General Surgery / General/ Clinical Pathology / Geriatric Medicine / Hematology / Medical Biochemistry / Medical Genetics / Medical Microbiology and Infectious Diseases / Medical Oncology / Nephrology / Neurology / Neurosurgery / Nuclear Medicine / Obstetrics/Gynecology / Occupational Medicine / Ophthalmology / Orthopedic Surgery / Otolaryngology / Pediatrics / Physical Medicine and Rehabilitation / Plastic Surgery / Psychiatry / Public Health and Preventive Medicine / Radiation Oncology / Respirology / Rheumatology / Urology / Osteopathic Medicine equivalente / Hepatology / Medical statistics / Men's health / Military medicine / Orthopedics / Otorhinolaryngology / Parasitology / Pathology / Clinical pharmacology / Sexual health / Sleep medicine / Space medicine / Sports medicine / Toxicology / Transplantation medicine / Tropical medicine / Virology / Women's health.

4. A minimum of 40 CME credits hours on the topic of obesity is required for certification. The credits must include the word “obesity” in the course title. All 40 CME credits hours must be earned within 36 months prior to the application deadline. The credits must include any ONLINE or IN-PERSON participation in educational events (Review Courses in Obesity Medicine / Self-assessment programs / Meetings / Congress / Conferences).

5. Aplicants have free access to the Review Course on Obesity Medicine offered by PABOM before the board exam. This course covers critical topics in the prevention and treatment of obesity and related disorders. It includes didactic lectures and panel discussions to improve participants’ ability to care for patients with obesity. During the 2 day review course, there will be interactive case-based studies and tips on test-taking strategies. Presentations will have question and answer sessions about the related topics designed to simulate board examination. Practical strategies to optimize the management of obesity and its many complications, and provides the most up-to-date approaches to obesity prevention and treatment.

This course is targeted to all medical specialties and Healthcare professionals with an interest in the latest approaches to the prevention and treatment of obesity and its complications, including: Physicians, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists, Dietitians, and Mental Health Professionals. 

The course provides certificate of completion, however get certified as an PABOM diplomate is exclusive for physicians with the minimum requeriments listed on this page.

This course is presented by authorities in medicine and diplomates of the PABOM, SBEMO, EBOM and Guest Professors.  

This course provides the knowledge to:


  • Identify, evaluate and manage patients with high-risk obesity

  • Comprehensive evaluation of the patient with obesity

  • Pathophysiology of obesity

  • Medical management of the patient with obesity

  • Emerging precision medicine approaches to obesity and metabolic disorders

  • Obesity comorbidities

  • Optimizing medical outcomes after bariatric surgery

  • Effective counseling and motivation techniques

  • Genetic and syndromic obesity

  • Nutrition and exercise assessment and intervention

  • Apply effective counseling and behavioral modification techniques

  • Pediatric patient management

  • Medical and surgical treatment of children and adolescents with obesity

  • Apply current pharmacological approaches to the treatment of obesity

  • Emerging strategies and therapies for genetic obesity

  • Navigating our understanding of how diet influences metabolic processes

  • Building and maintaining a successful Obesity Medicine practice

  • Provide lifestyle-based therapies for obesity, including nutritional, physical activity, and behavioral approaches

  • Assess patients for their need and appropriateness for bariatric surgery and determine surgical options

  • Enhancing communication about obesity with patients, referring providers, payers, and the public


  • I. Basic Concepts 

A. Determinants of Obesity 1. Lifestyle/Behavioral 2. Environmental/Cultural 3. Genetic 4. Secondary 5. Epigenetics and Fetal Environment

B. Physiology/Pathophysiology 1. Neurohormonal 2. Enterohormonal/Microbiota 3. Body Fat Distribution 4. Pathophysiology of Obesity-Related Disorders/ Comorbidities 5. Body Composition and Energy Expenditure 6. Energy Balance and Hormonal Adaptation to Weight Loss 7. Obesity Related Cell Physiology and Metabolism 8. Brain, Gut, Adipocyte Interaction

C. Epidemiology 1. Incidence and Prevalence, Demographic Distribution 

D. General Concepts of Nutrition 1. Macro and Micronutrients 2. Gastrointestinal Sites of Nutrient Absorption 3. Obesity Related Vitamin and Mineral Metabolism 4. Macronutrient Diet Composition and Effects on Body Weight and Metabolism

E. General Concepts of Physical Activity 

  • II. Diagnosis and Evaluation

A. History 1. Medications 2. Family History 3. Comorbidities/Assessment and evaluation 4. Sleep

B. Lifestyle/Behavior/Psychosocial 1. Demographic/Socioeconomic/Cultural/ Lifestyle/Occupational 2. Physical Activity 3. Nutrition/Diet 4. Eating Disorders/Disordered Eating 5. Body image disturbance

C. Physical Assessment 1. BMI 2. Waist Circumference 3. Physical Findings of obesity and Comorbid Conditions 4. Vital Signs 5. Underlying Syndromes 6. Signs of Nutritional Deficiency 7. Growth indices

D. Procedures and Laboratory Testing 1. Resting Metabolic Rate 2. Body Composition Analysis 3. Diagnostic Tests a. Comorbidities b. Secondary Obesity

  • III. Treatment

A. Behavior 1. Behavioral Counseling Techniques/Therapies 2. Self-Monitoring Techniques/Tools

B. Diet 1. Calorie and Micro/Macronutrient 2. Very Low Calorie Diet 3. Meal Replacements 4. Effect on Comorbid Conditions

C. Physical Activity 1. Prescription 2. Mechanisms of Action 3. Effect on Comorbid Conditions

D. Pharmacotherapy, Pharmacology and Pharmacokinetics 1. Risks, Benefits, and Adverse Effects 2. Indications/Contraindications 3. Monitoring and Follow Up 4. Prescription Dose and Frequency 5. Drug-Drug, Drug-Nutrient, Drug-Herbal Interactions 6. Off Label Usage/Over-the-counter (OTC) 7. Multi-drug/Combination Therapy 8. Management of Drug-Induced Weight Gain 9. Effect on Comorbid Conditions

E. Alternative, Emerging, and Investigational Therapies

F. Surgical Procedures 1. Types, Risks, Benefits 2. Indications and Contraindications 3. Complications 4. Pre-operative Assessment and Preparation 5. Post-operative Management a. Medical Inpatient b. Medical Outpatient c. Nutritional 6. Adolescent Surgery 7. Effect on Comorbid Conditions 

G. Strategies 1. Age-Related Treatment 2. Risks Associated with Excessive Weight Loss 3. Management of Weight Plateau 4. Prevention of Obesity and Weight Gain 5. Management of Comorbid Conditions During Weight Loss 6. Effect of Weight Loss on Comorbid Conditions 7. Treatment of Comorbid Conditions

H. Pediatric obesity 1. Treatment Guidelines 2. Pharmacotherapy 3. Bariatric Surgery 4. Family Support and Participation

        6.  The exam is a multiple-choice test comprised of 100 questions with a 3-hour time limit. The exam, as the PABOM Review Course on Obesity Medicine, will be offered in English, Spanish and Portuguese.


  • 2022 Early Application Deadline: December 30, 2022 - USD $ 580 fee (U.S. currency) 

  • 2023 Final Application Deadline: May 10, 2023 - USD $ 680 fee (U.S. currency)

Once required credentials and CME credit hours are completed, candidates may submit an application to sit for the certification exam. 

Click here to begin an application. 


PABOM applicants seeking certification through the CME Pathway are required to meet minimum continuing medical education (CME) credit hour requirements on the topic of obesity as set forth in the current PABOM Policies. All CME credit hours submitted to the PABOM are subject to review. 

The PABOM will not accept CME credit hours on topics outside the field of obesity medicine. The PABOM has sole discretion regarding whether a CME credit hour will be accepted for the CME Pathway.

The PABOM CME requirement is intended to direct self-study in an in-depth and comprehensive manner that prepares applicants to become PABOM Diplomates but does not guarantee an applicant’s success. The applicant who does not succeed in the exam, will be able to repeat it without any additional fee in the next certification exam.

If you have completed a live/virtual course and recordings of the same course, please submit only ONE set of credits to count toward the requirement. To qualify, you must submit  in obesity medicine along with your application, due December 30, 2022 (regular deadline) or May 10, 2023 (late deadline). 


PABOM recommends the following resources for exam preparation. The exam is a multiple-choice test comprised of 100 questions with a 3-hour time limit. The exam will be offered in Portuguese, English and Spanish. The examination is designed to assess the knowledge base and the cognitive and deductive skills of candidates. 

1.PABOM REVIEW COURSE IN OBESITY MEDICINE (Certification Exam Review Course)


  • AACE/ACE Obesity Task Force. AACE/ACE position statement on the prevention, diagnosis, and treatment of obesity (1998 Revision). Endocrine Practice. 1998;4(5):297.


  • Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes melito and its complications. Part 1: diagnosis and classification of diabetes melito provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-53


  • AACE guidelines: Timothy Garvey, MD, FACE; Jeffrey I. Mechanick, MD, FACP, FACE, FACN, ECNU; Elise M. Brett, MD, FACE, CNSC, ECNU; Alan J. Garber, MD, PhD, FACE; Daniel L. Hurley, MD, FACE; Ania M. Jastreboff, MD, PhD; Karl Nadolsky, DO; Rachel Pessah-Pollack, MD; Raymond Plodkowski, MD; and Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines /


  • Adult OMA Obesity guidelines: Obesity Algorithm® / Bays HE, McCarthy W, Christensen S, Tondt J, Karjoo S, Davisson L, Ng J, Golden A, Burridge K, Conroy R, Wells S, Umashanker D, Afreen S, DeJesus R, Salter D, Shah N, Richardson L. Obesity Algorithm eBook, presented by the Obesity Medicine Association. 2020.


  • Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocrine Rev. 1999;20:805-75.


  • Bray GA. Historical framework for the development of ideas about obesity. In: Bray GA, Bouchard C, James WPT, editors. Handbook of obesity. NewYork: Marcel Dekker; 1998. p. 1-29.


  • Bray GA. Obesity – A time bomb to be refused. Lancet. 1998;352:160-1.


  • Bariatric Surgery Complications: The Medical Practitioner’s Essential Guide, 1st edition (2017) – edited by Robin Blackstone

  • Bariatric Surgery Complications and Emergencies, 1st edition (2016) – edited by Daniel Herron

  • European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Clinical investigation of drugs used inweight control. The European Agency for the Evaluation of Medicinal Products, London; 1997.

  • Food and Drug Administration. Guidance for the clinical evaluation of weight control drugs. Rockville, MD: Food and Drug Administration; 1996.

  • Handbook of Obesity Treatment, 2nd edition (2018) – edited by Thomas Wadden and George Bray

  • Handbook of Obesity, 4th edition (2014) – Volumes 1 and 2 – edited by George Bray and Claude Bouchard

  • James WP, Caterson ID, Coutinho W, Finer N, van Gaal LF, Maggioni AP, et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomesin overweight and obese subjects. N Engl J Med. 2010;363(10):905-17.

  • Jung CH, Jang JE, Park JY. A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor. Diabetes Metab J. 2014;38(4):261-73.

  • Kakkar AK, Dahiya N. Drug treatment of obesity: Current status and future prospects. Eur J Intern Med. 2015;26(2):89-94.

  • Leung WYS, Thomas GN, Chan JCN, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther.2003;25:58-80.

  • Managing Obesity: A Clinical Guide, 2nd edition (2009) – edited by Cathy Nonas and Gary Foster

  • Mordes JP, Liu C, Xu S. Medications for weight loss. Curr Opin Endocrinol Diabetes Obes. 2015;22(2):91-7.

  • Obesity Prevention and Treatment: A Practical Guide, 1st edition (2022) – edited by James Rippe and John Foreyt 

  • Obesity Management – ACC/AHA/TOS guidelines:Michael D. Jensen, Donna H. Ryan, Caroline M. Apovian, Jamy D. Ard, Anthony G. Comuzzie, Karen A. Donato, Frank B. Hu, Van S. Hubbard, John M. Jakicic, Robert F. Kushner, Catherine M. Loria, Barbara E. Millen, Cathy A. Nonas, F. Xavier Pi-Sunyer, June Stevens, Victor J. Stevens, Thomas A. Wadden, Bruce M. Wolfe, Susan Z. Yanovski /


  •  Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31(2):142-52.


  • Pediatric Obesity: Etiology, Pathogenesis, and Treatment, 2nd edition (2018) – edited by Michael Freemark


  • Primary Care: Evaluation and Management of Obesity, 1st edition (2022) – edited by Robert Kushner, Daniel Bessesen, Adam Gilden

  • Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline: Dennis M. Styne, Silva A. Arslanian, Ellen L. Connor, Ismaa Sadaf Farooqi, M. Hassan Murad, Janet H. Silverstein, Jack A. Yanovski. J Clin Endocrinol Metab (2017) 102 (3): 709-757.

  •  Pediatric OMA guidelines: Pediatric Obesity Algorithm® Cuda S, Censani M, Joseph M, Browne N, O’Hara V. Pediatric Obesity Algorithm, presented by the Obesity Medicine Association. 2018-2020.

  • Pediatric Obesity: Prevention, Intervention and Treatment Strategies for Primary Care, 2nd edition (2014) – Edited by Sandra Hassink

  • Rossner S. Factors determining the long-term outcome of obesity treatment. In: Bjorntorp P, Brodoff BN, editors. Obesity. New York: J.B. Lippincott Co;1992. p. 712-9.

  • Shukla AP, Buniak WI, Aronne LJ. Treatment of obesity in 2015. J Cardiopulm Rehabil Prev. 2015;35(2):81-92.

  • Snow V, Barry P, Fitterman N, Qaseem A, Weiss K; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologicand surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians. Ann Intern Med.2005;142:525-31.

  • The SAGES Manual of Bariatric Surgery, 2nd edition (2018) – edited by Kevin Reavis, Allison Barrett, Matthew Kroh

  • The ASMBS Textbook of Bariatric Surgery, 2nd edition (2020) – edited by Ninh T. Nguyen, Stacy A. Brethauer, John M. Morton, Jaime Ponce, Raul J. Rosenthal 

  •  van Gaal LF, Wauters MA, de Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord.1997;21:S5-9.

  • Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity.N Engl J Med. 2005;353:111-20.

  • WHO Consultation on Obesity. Preventing and managing the global epidemic. Geneva: World Health Organization; 1998.

  • Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucosecotransporter 2 inhibitors. Metabolism. 2014;63(10):1228-37.

01-03-2022 V3-E-English Logo Branca.png


11412 NE 8º Ct

Biscayne Park , Miami
Florida - EUA

 Zip Code 33161

WhatsApp: +1 (760) 593-8179 

bottom of page